1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Sutro Biopharma, Inc.

Sutro Biopharma, Inc.

STRO
Sutro Biopharma, Inc.US flagNASDAQ Global Market
11.42
USD
+0.17
- -
189.39MMarket Cap

Total Valuation

Sutro Biopharma, Inc. carries a market capitalization of 189.39M, placing it among publicly traded companies globally. Its enterprise value stands at 396.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap189.39M
Enterprise Value396.77M

Share Statistics

Sutro Biopharma, Inc. currently has 16.58M shares outstanding.

Shares Outstanding16.58M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 9.24, and the price-to-book ratio stands at -5.33.

PE RatioN/A
PS Ratio9.24
PB Ratio-5.33
P/TBV Ratio-5.33
P/FCF Ratio-2.92
P/OCF Ratio-2.91

Enterprise Valuation

EV / Sales8.68
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Sutro Biopharma, Inc. maintains a current ratio of 3.32, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -10.44, indicating conservative leverage, while an interest coverage ratio of -3.03 demonstrates limited ability to service its debt obligations.

Current Ratio3.32
Quick Ratio3.22
Debt / Equity-10.44
Debt / EBITDA-0.09
Interest Coverage-3.03

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-79.08
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax-96,000.00
Effective Tax RateN/A

Stock Price Statistics

Sutro Biopharma, Inc.'s stock has gained approximately 0.19210526% over the past 52 weeks. The 50-day moving average sits at 17.66, while the 200-day moving average is 23.11.

Beta (5Y)N/A
52-Week Price Change0.19210526%
50-Day Moving Average17.66
200-Day Moving Average23.11
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Sutro Biopharma, Inc. generated 45.70M in revenue and converted that into -180.64M in net income, yielding earnings per share of -14.21. EBITDA reached -125.79M, while operating income came in at -131.86M.

Revenue45.70M
Gross ProfitN/A
Operating Income-131.86M
Pretax Income-180.73M
Net Income-180.64M
EBITDA-125.79M
EBIT-131.86M
Earnings Per Share (EPS)-14.21

Balance Sheet

Sutro Biopharma, Inc. holds 164.35M in cash and equivalents against 10.78M in total debt, resulting in a net debt position of -54.33M. Total book value stands at -103.32M, with working capital of 122.75M providing operational flexibility.

Cash & Cash Equivalents164.35M
Total Debt10.78M
Net Debt-54.33M
Equity (Book Value)-103.32M
Book Value Per Share-6.23
Working Capital122.75M

Cash Flow

Sutro Biopharma, Inc. produced -145.17M in operating cash flow over the past twelve months. After subtracting -446,000.00 in capital expenditures, free cash flow totaled -145.62M - equivalent to -11.45 per share.

Operating Cash Flow-145.17M
Capital Expenditures-446,000.00
Free Cash Flow-145.62M
FCF Per Share-11.45

Margins

Sutro Biopharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -288.52 and net profit margin of -395.25 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-288.52
Pretax Margin-395.46
Profit Margin-395.25
EBITDA Margin-275.25

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-18.66
FCF Yield-34.29

Stock Splits

Sutro Biopharma, Inc.'s most recent stock split took place on December 3, 2025 with a 10:1 split ratio.

Last Split Date12/3/2025
Split Ratio10:1

Scores

Sutro Biopharma, Inc. posts an Altman Z-Score of -7.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-7.73